Choroidal melanoma is the most common primary intraocular malignancy. Diagnosis is performed by clinical evaluation: eye cancer specialists currently use multiple diagnostic techniques, including ophthalmoscopy, fundus autofluorescence imaging (FAF), fluorescein angiography (FA), and indocyanine green angiography (ICG), as well as optical coherence tomography (OCT). Tumor biopsy has recently become popular due to the availability of diagnostic cytogenetic features, touted as biomarkers for metastasis. Standard treatments include observation (select small melanomas and indeterminate tumors), radiation therapy (plaque, proton beam), eye wall resection, and removal of the eye.
a pigmented choroidal tumor with the orange pigment lipofuscin (OPL) on the tumor's surface, significant thickness, and exudative retinal detachment are diagnostic of CM. 24 For smaller tumors, photography and ultrasound-assisted documentation of growth may be required.
Over the last 30 years, the misdiagnosis rate for CM has been greatly reduced. For example, the use of experienced examiners, indirect ophthalmoscopy, FA, and ultrasound imaging reduced the COMS misdiagnosis rate to less than 1 %. 25, 26 Ophthalmic Imaging Techniques For example, after treatment exudative fluid and OPL typically regress and the tumor darkens. Photographic documentation of these changes allows the eye cancer specialists to establish the pattern of CM regression.
Late radiation changes (including radiation retinopathy and optic neuropathy) can be initially documented and comparatively evaluated for progression or regression by fundus photography. 27 FAF has emerged as a powerful tool to document and discover occult OPL. Exudative retinal detachments can also be seen with FAF, particularly when there is an associated acute or chronic retinal pigment epithelial degeneration. 3, 28 OCT is the most sensitive method of detecting subretinal fluid and intraretinal edema. 29 OPL can also be seen as deposits on the retinal pigment epithelium. Some studies suggest that choroidal nevi and their overlying intact retinal pigment epithelium are less likely to allow transmission of light into the tumor's stroma and subjacent choroid.
Intraocular Angiography
FA and ICG are used to evaluate CM. Angiographic imaging can reveal unique patterns of tumor circulation. For example, a 'double circulation' with well-defined blood vessels is rarely seen in metastatic tumors and a 'coarse vascular pattern' is characteristic of choroidal hemangioma.
Metastatic choroidal tumors typically have poor circulation, characterized by slow uptake, leakage, and stromal dot-like microaneurysms. In select cases, FA or ICG may be the best methods to determine largest basal tumor dimensions prior to the choice of plaque size.
Beyond diagnosis, post-treatment surveillance of tumor circulation can help determine response to radiation, adjuvant laser therapies, and the onset of secondary vasculopathy (e.g. radiation maculopathy
and optic neuropathy).
Ultrasound Imaging
Ultrasound imaging has come to play an essential role in the diagnosis, treatment, and follow-up of patients with CM. Pioneered by Karl Ossoinig and Sandra Frazier Byrne, standardized ophthalmic ultrasound techniques Current Methods for the Diagnosis and Treatment of Choroidal Melanoma were employed by the COMS and thus established low internal reflectivity and dome shape as the most common presenting characteristics of CM (see Figure 2a) . 30 Mushroom-shaped CM were noted in only 25 % of cases and found to be more common among larger tumors (see Figure 2b ). The COMS report number 29, describing baseline echographic characteristics of 2,320 patients with medium and large tumors, found that 1,268 patients (54 %) had a tumor apex located posterior to the equator (27 % equator-posterior, 22 % posterior-equator, and only 5 % posterior).
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A-scan imaging is the most sensitive method to assess a tumor's internal acoustic reflectivity. This characteristic has been exploited to differentiate between types of tumors and to monitor response to therapy. For example, internal reflectivity is typically high with choroidal hemangioma, moderate with metastases, and low with CM. 31 Non-hemorrhagic retinal pigment epithelial detachments and choroidal effusions are typically echolucent. During the years after radiation therapy for choroidal melanoma, A-scan typically reveals increasing internal reflectivity.
B-scan imaging has become an essential tool for measuring tumor dimensions. Commonly, CMs are measured to be larger by ultrasound compared with fundus photography. This information is vital for treatment planning (accurate plaque size selection) and for assessing response to radiotherapy. Furthermore, both dynamic A-and B-scan imaging can be used to assess a tumor's intrinsic vascularity at diagnosis and document post-treatment reductions over time.
Use of 3D B-scan ultrasound imaging has proved invaluable for evaluating disorganized eyes (e.g. those containing occult CM).
Interactive sectioning of the 3D block has allowed for post-enucleation ultrasonographic-histopathologic reconstruction. Lastly, such sectioning also allows for simultaneous longitudinal and transverse views of ophthalmic plaques in vivo, aiding intra-operative evaluations of plaque placement. 25 Ophthalmic ultrasound imaging has been recognized as an integral method for evaluating and T-staging uveal melanomas by both With advances in cytogenetics, in recent years it appeared likely that biopsy would also be used to grade uveal melanomas. In the 1990s, it was discovered that uveal melanomas tend to develop several chromosomal abnormalities, the most important of which re monosomy 3, isochromosome 6p, trisomy 8, and isochromosome 8q.
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A landmark article by Prescher et al. showed monosomy 3 to correlate strongly with metastatic death, data indicating a reduction in the five-year survival from 100 to less than 50 %. 38 However, these initial expectations regarding the sensitivity and specificity of monosomy 3 tests in predicting metastatic death were found to be overly optimistic.
Perhaps cytogenetic prognostication may require taking into account the complex pathway we call metastasis and that immune status, tumor size, and access to routes of egress may also play a role. 
Biomarkers for Metastases
The first biomarkers for CM were histopathologic as offered by Callender's classification, in which predominantly spindle cell melanomas carried the best prognosis, mixed-cell tumors were worse, and epithelioid cell tumors the most likely to metastasize. 41 Other features associated with systemic prognosis include intrinsic tumor vascular patterns, tumor vascular density, tumor size, location of the anterior margin of the tumor, and degree of ciliary body involvement. 42, 43 It is important to note that in consideration of most of the above, as well as epidemiologic and other clinical factors, the COMS offered the first evidence-based results that patient age and largest tumor dimension were the most significant biomarkers for metastasis by multivariate analysis. 16 In 2006, Finger and colleages suggested that PET/CT imaging specfic uptake value (SUV) could be used as a biomarker for metastatic risk. 10 This observation was recently confirmed by Lee et al., 2011.
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Metastatic Disease Detection
Although CM is not as aggressive as skin melanoma, Kujala et al.
reported mortality rates of 31 % by five years, 45 % by 10 years, 49 % by 25 years, and 52 % by 35 years. 45 In this article, we found that the diagnosis and treatment of metastatic CM varies by country, region, and clinical centers. It is also driven by patient and social and economic factors.
In general, pre-operative metastatic surveys should include a physical examination looking for cutaneous and subcutaneous nodularity as well as hepatomegaly. Radiographic imaging can range from contrast-enhanced abdominal MRI, CT or ultrasound imaging to total body PET/CT.
In that over 90 % of patients present with hepatic involvement, abdominal imaging should be integral to pre-operative staging and subsequent surveillance. However, in a recent study using whole-body PET/CT, 75 % of patients with metastatic CM were noted to have extrahepatic -primarily bone (50 %), lung (25 %), lymph node (25 %), and skin (25 %) -metastases (see Figure 3 ). This distribution suggests that liver function tests alone are inadequate. 24, 46, 47 There are centers that do not perform metastatic surveys due to a lack of definitive treatment for metastatic CM. At The New York Eye Cancer
Center, we currently perform pre-operative surveys to find the <4 % that have detectable disease at presentation. 12 Such discovery can eliminate the need for surgery for the primary CM, reveals synchronous non-ocular tumors, and allows for both systemic staging and early intervention.
Follow-up metastatic surveys allow for both early intervention and end-of-life planning.
Tumor Staging
Clinical practice varies greatly from one center to another. Though the COMS defined CMs as small, medium, and large, the Ophthalmic Oncology Task Force of the AJCC, together with the UICC, has recently produced a universally accepted seventh edition AJCC staging system.
This five-year effort involved 45 eye cancer specialists from 11 countries. 48 Specifically, Chapter 51, Malignant Melanoma of the Uvea, was the result of a retrospective multinational evaluation of over 8,000
patients. This system is now considered 'universal' after being widely accepted as a requirement for publication by over 10 major ophthalmic journals and their associated societies. They recognized that standardized reporting would allow for more accurate comparison of diagnostic and therapeutic techniques, as well as the development of biomarkers for CM. Current Methods for the Diagnosis and Treatment of Choroidal Melanoma 
Diagnosis of Choroidal Melanoma-Summary
U S O P H T H A L M I C R E V I E W
Positron emission tomography (PET) reveals a radioactive glucose (18-FDG) uptake measure of physiologic activity, while computed tomography (CT) reveals its anatomic shape and location. This combined PET/CT image puts form and function on the same diagnostic page.
The Treatment of Choroidal Melanoma
Treatment CM treatment is performed to prevent metastatic disease, to maximize visual acuity, and to preserve the eye. With these goals in mind, there has been an evolution of treatment from primary enucleation and local resection to laser photocoagulation and radiation therapy. At this time, radiation therapy is the most widely accepted alternative to enucleation. 49 
Enucleation
In most developed countries, enucleation surgery is performed when the CM is considered to be too large for vision-sparing techniques, for extensive extrascleral tumor extension, and for neovascular glaucoma. 50 Alternatively, in undeveloped countries eye-and vision-sparing radiation techniques may not be available. The COMS large tumor trial found that 20 Gy (4 Gy per day x five 5 days) did not improve survival after enucleation surgery. 51 This finding suggests that the Zimmerman Hypothesis (that we disseminated metastasis by manipulation during enucleation surgery) was incorrect. 52 It is important to note that orbital tumor recurrence was reported in less than 1 % of cases. If this occurs, it can be treated by local resection of all visible tumor, followed by 50 Gy external beam radiotherapy. 53 At The New York Eye Cancer Center, most patients can be fitted with an ocular prosthesis that requires minimal maintenance and has excellent cosmesis. 54 Prosthetic ocular motility is typically less than the natural eye and mucus discharge is common. Patients should be counseled to wear unbreakable polycarbonate glasses to protect the remaining eye.
Local Resection Techniques Endoresection
Endoresection comprises the removal of a posteriorly located uveal melanoma through a pars plana vitrectomy, typically after radiation therapy. 55 Surgery is performed with a vitrector through a retinotomy or beneath a retinal flap. An air-fluid exchange drains residual subretinal fluid; endolaser photocoagulation is used to destroy any residual intrascleral tumor and to achieve retinopexy.
Silicone oil is typically required. Theory suggests that endoresection reduces tumor-related ocular morbidity but adds the risk of vitreoretinal complications (silicone oil removal, secondary rhegmatogenous retinal detachment, intraocular hemorrhage) and tumor dissemination. 
Transpupillary Thermotherapy
In the 1950s, Dr Meyer-Schwickerath attempted primary treatment of CM with the xenon-arc laser. 61 Since that time others have used argon, krypton, dye, and, most recently, the infrared spectrum. To date, no laser method has produced acceptable local control, but has added risks including hemorrhage, retinal detachment, edema and traction, scleromalacia with orbital tumor extension, and laser-induced optic neuropathy.
Transpupillary thermotherapy (TTT), as originally described by
Oosterhuis and popularized by Shields, 62-65 was suggested for the treatment of small tumors, up to 4 mm in height, lying near the optic disk or the fovea (in an effort to spare these structures from damage).
With a modified delivery system beam widths between 1 and 3 mm and exposure times of up to one minute are typically generated. 66 This method was reported to offer a local tumor control rate of 76 % (not as successful as radiation therapy). 67 However, due to failures of local control (intraocular and orbital), TTT has largely been abandoned as a primary treatment for CM. 68 
graphic demonstration of the relative dose distribution of transocular proton beam radiation. Note that the tantalum clips have been surgically placed, now the patient requires head immobilization, and a video camera is used to monitor eye movements.
Radiation Therapy for Choroidal Melanoma
You can destroy a choroidal melanoma with any form of radiation therapy, but dose-related differences (side effects) will be seen in the normal ocular structures. Therefore, our primary goal of destroying the tumor will be accomplished, but there will be distinct differences in resultant rates of visual acuity and eye preservation.
Teletherapy
Teletherapy means treatment from a distance. In ophthalmic oncology CM has been treated with cylindrically shaped beams of charged particles -protons or helium ions. Prior to treatment, tantalum clips are sewn to the episclera around the base of the tumor to localize the targeted zone.
The particle-generating cyclotron is directed toward the eye in line with the CM as defined by the clips (see Figure 4) . Eye movement is monitored on a screen and the beam turned off if the eye wanders. Typical daily fractions are 10-16 Gy, for five consecutive days (50-80 Gy). Each relatively high-dose-rate fraction is given during less than five minutes, compared with continuously over 5-7 days with brachytherapy. Therefore, in part due to high-dose-rate effects, the proton dose is much higher than numerically equivalent brachytherapy apex doses. Therefore, it is understandable that proton-beam local control rates are among the highest. 49, 75, 76 However, the cylindrically shaped beam must traverse the anterior segment to reach the CM. As Packer predicted, proton-beam-related anterior segment doses were relatively high, resulting in more reports of eyelash loss, dry eye, neovascularization of the iris, neovascular glaucoma, and cataract. These complications became even greater in treatment of large and anteriorly located tumors. Similarly, radiation retinopathy and optic neuropathy were more commonly reported in treatment of posteriorly located CM. It is important to note that iodine-125 and palladium-103 plaques deliver photons that can extend deeply into the eye. In contrast, ruthenium-106 plaques emit beta-particles that can only extend far enough to treat 5 mm high tumors reliably. 22, 25 Furthermore, the dose to the tumor base and tumor margin can be four times higher in treatment of the same 5 mm-tall CM using iodine-125 versus ruthenium-106. The high base dose will cause earlier chorioretinal atrophy. 17, 77, 83 Like proton therapy, low-energy plaque irradiation of larger tumors has been associated with more radiation complications. However dry eye, eyelash loss and neovascular glaucoma are relatively uncommon (see Table 1 ).
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The most frequent low-energy plaque-related complications are radiation retinopathy, radiation optic neuropathy, and cataract. 17, [68] [69] [70] At The New York Eye Cancer Center, the largest CM basal dimension treated with ophthalmic plaque is 22 mm and the tallest has been 16 mm. Dr Finger's slotted plaques successfully control tumors that encircle the optic nerve (circumpapillary). 71 Therefore, few patients cannot be treated with eye-and vision-conserving ophthalmic plaque radiation therapy.
Anti-Vascular Endothelial Growth Factor Therapy
Prior to the advent of bevacizumab and ranibizumab (Avastin ® or Lucentis ® , Roche-Genentech, South San Francisco, California, US), more than 50 % of patients were reported to have less than 20/200 vision five years after CM radiation therapy (see Table 1 ). Though this was all-cause visual morbidity, the most common causes of severe irreversible loss of vision were radiation maculopathy and radiation optic neuropathy. In 1997, Finger reported on short-term findings of reductions in retinal and optic nerve edema, as well as decreased retinal hemorrhage, associated with periodic intravitreal injections of bevacizumab. Later reports, and those of others, have supported these findings. [84] [85] [86] It has been Finger's impression that higher radiation doses to fovea and optic nerve are harder to overcome with this method.
Conclusion
The primary goal of CM treatment is to destroy or remove the malignancy to prevent metastasis. Though enucleation and surgical resection are available, most patients are currently treated with plaque radiation therapy. The most widely used sources are iodine-125 and ruthenium-106 plaques, with a few referral centers using proton beam and palladium-103.
Cyberknife and stereotactic radiosurgery are most exotic forms of EBRT and should be considered investigational. We know that all methods of radiation therapy can destroy a CM. However, evidence now exists that radiation dose to fovea, lens, and optic nerve can be used to predict rates of complications. 81, 82 Therefore, it is reasonable to compare the available radiation modalities, perform computer-aided simulations, calculate doses to critical structures, and choose the 'best' method prior to treatment.
Ophthalmic oncology has progressed from primary enucleation to modern and exotic methods of eye-and vision-sparing radiation therapy.
Thankfully, in the modern era, fewer patients have to lose their eye due to the presence of CM. n LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries. Only practitioners who are experienced in the medical management and surgical treatment of the cornea, who have been trained in laser refractive surgery including laser system calibration and operation, may use the device as approved. Prospective patients, as soon as they express an interest in an indicated LASIK procedure and prior to undergoing surgery, must be given the WaveLight ® System Patient Information Booklet and must be informed of the alternatives for refractive correction including eyeglasses, contact lenses, PRK, and other refractive surgeries. Clinical Data Myopia: The WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO WAVE ® Eye-Q Excimer Laser System for LASIK treatments of myopic refractive errors up to -12.0 D of sphere with and without astigmatic refractive errors up to -6.0 D at the spectacle plane was studied in clinical trials in the United States with 901 eyes treated, of which 813 of 866 eligible eyes were followed for 12 months. Accountability at 3 months was 93.8%, at 6 months was 91.9%, and at 12 months was 93.9%. The studies found that of the 844 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 3-month stability time point, 98.0% were corrected to 20/40 or better, and 84.4% were corrected to 20/20 or better without spectacles or contact lenses. The clinical trials showed that the following subjective patient adverse events were reported as moderate to severe at a level at least 1% higher than baseline of the subjects at 3 months post-treatment: visual fluctuations (12.8% at baseline versus 28.6% at 3 months). Long term risks of LASIK for myopia with and without astigmatism beyond 12 6 .0 D at the spectacle plane has been studied in clinical trials in the United States with 162 eyes treated, of which 111 were eligible to be followed at 6 months. Accountability at 1 month was 99.4%, at 3 months was 96.0%, and at 6 months was 100.0%. The studies found that of the 142 eyes eligible for the UCVA analysis of effectiveness at the 3-month stability time point, 95.8% achieved acuity of 20/40 or better, and 67.6% achieved acuity of 20/20 or better without spectacles or contact lenses. The clinical trials showed that the following subjective patient adverse events were reported as moderate to severe at a level at least 1% higher than baseline of the subjects at 3 months post-treatment: sensitivity to light (43.3% at baseline versus 52.9% at 3 months); visual fluctuations (32.1% at baseline versus 43.0% at 3 months); and halos (37.0% at baseline versus 42.3% at 3 months). Long term risks of LASIK for mixed astigmatism beyond 6 months have not been studied.
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interface; 0.1% (1/844) had foreign body sensation; 0.2% (2/844) had pain; and 0.7% (6/844) had ghosting or double images in the operative eye. The following complications did NOT occur 3 months following LASIK in this clinical trial: corneal edema and need for lifting and/or reseating
Clinical Data Wavefront-guided Treatment of Myopia:
The WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO WAVE
